Contrast Enhanced Ultrasound and Muscle (Echomuscle)

• ClinicalTrials.gov Identifier: NCT02128750
• Recruitment Status: Completed
• First Posted: May 1, 2014
• Last Update Posted: March 7, 2016
• Sponsor: University Hospital, Grenoble
• Information provided by (Responsible Party): University Hospital, Grenoble

Tracking Information

• First Submitted Date: April 29, 2014
• First Posted Date: May 1, 2014
• Last Update Posted Date: March 7, 2016
• Study Start Date: February 2011
• Actual Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: April 29, 2014)

Time to Peak [ Time Frame: M0 (before revascularisation) and M1 (One month after the revascularisation). ]

Time to peak modification, before and one month after the revascularization

• Original Primary Outcome Measures: Same as current
• Change History: Complete list of historical versions of study NCT02128750 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures (submitted: April 29, 2014)

• Curves datas [ Time Frame: M0 (before revascularisation) M1 (one month after revascularisation). ]
  Evaluation of other data issued from the kinetic curve of enhancement (time between injection and peak, area under curve, quantitative value of peak, time of vein-muscle transit (TTP muscle -TTP vein) before and after revascularization.
• kinetics values [ Time Frame: M0 (before revascularisation) and M1 (one month after revascularisation). ]
  Study of correlation between kinetic data (TTP) and measures of TcPO2 and toe systolic pressure before revascularization and one month after revascularization
• Time to peak [ Time Frame: M0, M1 and M3 (three month after revascularisation) ]
  Study of predictive value of TTP before revascularization on success of revascularization at 1 month (clinical evaluation on pain, lack of minor or major amputation, healing of ulcer) and at 3 months (survival, lack of minor or major amputation, new surgery).

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Contrast Enhanced Ultrasound and Muscle
• Official Title: Echographie de Contraste Pour l'Analyse de la Perfusion Musculaire Dans l'ischémie Critique
• Brief Summary: The primary objective of our work is to show that quantification of muscular microvascularisation evaluated by injection of contrast agent is different between chronic critical limb ischemia (before revascularization) and after (healing of ischemia) and thus make the proof of its utility in evaluation of PAD therapeutics.

Detailed Description

• Peripheral arterial disease (PAD) is a frequent disease the incidence of which in men is about 32.5°/°° before 40 years and 71°/°° after 50 years. Prevalence of the disease increases with age to reach 3.7% of 60 to 69 year old subjects (Kannel 1970, 1985, Bloch 1985).
• Critical limb ischemia (CLI) ischemia is defined by typical chronic ischemic rest pain or ischemic skin lesions either ulcers or gangrene for more than two weeks (Norgren). Incidence is about 500 - 1000 / 106 / year in Europe and United states. Critical limb ischemia concerns 15 - 20% of patients with intermittent claudication (Eneroth 1992, Taylor 1989). Development can lead to limb loss with a frequency estimated between 7% at 5 years to 12% at 10 years. Problem is crucial for patients who cannot benefit from revascularization. Results of single medical treatments are uncertain. Development of neovascularisation by innovating therapeutic (autolog cell stem grafts, intramuscular growth factor injections ) represent an exciting and promising field of research.
• Peripheral arterial disease evaluation and staging are based on measures of resting ankle pressures, diagnosis of stenosis and obliteration (duplex, angiography, computed tomography scan and magnetic resonance imaging) and on measure of microcirculatory skin perfusion by Tc PO2. On the other hand, there is no simple tool to measure muscular microvascularisation whereas muscles suffer from ischemia in the same way as skin and nerves. Measures of muscular perfusion can be performed by Tc 99, magnetic resonance imaging but this is not used in clinical practice. CEUS used in routine to assess hepatic microvascularisation has recently been shown to be potentially useful to study muscle (Kramer 2008, Weber 2007).
• Ultrasonic contrast agents are intravascular microbubbles which used at low mechanical index generate harmonics and allow real time imaging in ultrasonography. Their use allows study of parenchyma enhancement in real time, notably of liver and kidneys; they are also used in practice to differentiate benign and malign tumors (Correas 2009). Correlations have been shown between muscle enhancement studied by CEUS and histologic data of capillary vascularisation (Weber 2005). More recently some authors have shown that CEUS may allow to differentiate patients with PAD at a stage of intermittent claudication and patients without PAD (Duerschmied 2006).Very few studies have studied patients with CLI. Duerschmied and all have shown that kinetic data of muscle enhancement may reflect collateral circulation developed in reaction to chronic ischemia. CEUS may be used to study muscular perfusion in the same way as TcPO2 reflects cutaneous vascularisation and may become an evaluation criteria of PAD therapeutics in a near future.
• We propose to study muscular perfusion by CEUS in patients with critical limb ischemia eligible to revascularization (PTA or bypass) before and after revascularization. Microbubbles injection leads to an increase in muscle echogenicity in two sequences: a rapid phase 15-20 s after injection (arteriolar filling) then a more intense second phase (veinular and capillary filling) (Duerschmied 2006). These two phases may be described by measures of acoustic intensity function of time and in particular time to peak (TTP), area under the curve (AUC). Time to peak seems to be the more reliable criteria (Duerschmied).

• Study Type: Interventional
• Study Phase: Not Applicable
• Study Design: Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Diagnostic

Condition

• Ischemia
• Thromboangiitis Obliterans

Intervention

Other: contrast echographie with hexafluorur of sulfur

Echography of contrast after injection of product of contrast (sonovue (r))

Study Arms

Experimental: revascularization group

Subjects in this arms have an contrast echographie with sonovue(r) then a revascularization and finnaly an other contrast echographie with sonovue.

Intervention: Other: contrast echographie with hexafluorur of sulfur

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: April 29, 2014): 32
• Original Actual Enrollment: Same as current
• Actual Study Completion Date: March 2014
• Actual Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Men and women over 40 years
• Patients with chronic critical limb ischemia as defined by consensus TASC 2 and eligible to a revascularisation
• Objective evaluation of critical ischemia is based on ankle pressure < 70 mm Hg or toe pressure < 50 mm Hg for patients with ulcer or pressure ankle pressure < 50 mm Hg or toe pressure < 30 mm Hg for patients with rest pain.
• Patient's consent signed

Exclusion Criteria:

• Patients under 18
• Pregnant or breast feeding woman
• Burger's disease

• Contra- indication to use of contrast

  • Hypersensitivity to sulfurhexafluorure
  • Unstable coronary heart disease, acute stroke, uncompensated heart failure
  • Right to left shunt
  • Serious pulmonary hypertension (> 90 mm Hg)
  • Uncontroled increased blood pressure
  • Acute respiratory distress syndrom
• Consent refused
• Patients with leg wounds preventing ultrasonography

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: France

Administrative Information

• NCT Number: NCT02128750
• Other Study ID Numbers: EBCS1
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Responsible Party: University Hospital, Grenoble
• Study Sponsor: University Hospital, Grenoble
• Collaborators: Not Provided

Investigators

• Principal Investigator: Christophe Seinturier, Doctor; University Hospital Grenoble - Medecine vasculaire

• PRS Account: University Hospital, Grenoble
• Verification Date: April 2014